The
vitamin D endocrine system is essential for
calcium and bone homeostasis. The precise mode of action and the full spectrum of activities of the
vitamin D hormone,
1,25-dihydroxyvitamin D [
1,25-(OH)(2)D], can now be better evaluated by critical analysis of mice with engineered deletion of the
vitamin D receptor (VDR). Absence of a functional VDR or the key activating
enzyme, 25-OHD-1alpha-hydroxylase (
CYP27B1), in mice creates a bone and growth plate phenotype that mimics humans with the same congenital disease or severe
vitamin D deficiency. The intestine is the key target for the VDR because high
calcium intake, or selective VDR rescue in the intestine, restores a normal bone and growth plate phenotype. The VDR is nearly ubiquitously expressed, and almost all cells respond to 1,25-(OH)(2)D exposure; about 3% of the mouse or human genome is regulated, directly and/or indirectly, by the
vitamin D endocrine system, suggesting a more widespread function. VDR-deficient mice, but not
vitamin D- or 1alpha-hydroxylase-deficient mice, and man develop total
alopecia, indicating that the function of the VDR and its
ligand is not fully overlapping. The immune system of VDR- or
vitamin D-deficient mice is grossly normal but shows increased sensitivity to
autoimmune diseases such as
inflammatory bowel disease or
type 1 diabetes after exposure to predisposing factors. VDR-deficient mice do not have a spontaneous increase in
cancer but are more prone to oncogene- or chemocarcinogen-induced
tumors. They also develop high
renin hypertension,
cardiac hypertrophy, and increased thrombogenicity.
Vitamin D deficiency in humans is associated with increased prevalence of diseases, as predicted by the VDR null phenotype. Prospective
vitamin D supplementation studies with multiple noncalcemic endpoints are needed to define the benefits of an optimal
vitamin D status.